Geron continues to build their case

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1003
Joined: Fri Jul 20, 2018 5:13 pm

Geron continues to build their case

Post by biopearl123 » Sun Sep 25, 2022 8:22 pm


kmall
Posts: 295
Joined: Thu Mar 21, 2019 3:57 pm

Re: Geron continues to build their case

Post by kmall » Tue Sep 27, 2022 8:43 am

Another noteworthy detail here is the category this falls under:

Clinical Lymphoma Myeloma and Leukemia

And as you pointed out Bp:

Nishan Sengupta - VP, Market-Access, Pricing, Evidence Strategy, Geron Corporation, who was hired in August 2021..........and is also currently employed at JNJ as Global/US Access Strategy Lead-IMBRUVICA, B-Cell, Rare Hematology, holding that title since August 2019.

Prior to this he was JNJ Global Market Access Leader -Oncology/Hematology from Jan 2012 - Aug 2021.........his titles time period would encompass the entire duration of the Geron/JNJ collaboration (2014 - 2018).


Even though the abstract here focuses on LR MDS, the B-Cell in Nishan Sengupta's title at JNJ (present) represents B-Cell Lymphoma.

B-Cell: a lymphocyte not processed by the thymus gland, and responsible for producing antibodies.

B-Cell Lymphomas include: Follicular lymphoma, Burkitt's lymphoma, Mantle cell lymphoma, Waldenström macroglobulinemia, Marginal zone B-cell lymphoma, Hairy cell leukemia, Nodal marginal zone B cell lymphoma, Non-Hodgkin lymphoma, Splenic marginal zone lymphoma, MALT lymphoma, Extranodal NK/T-cell lymphoma, nasal type, Small cell lymphoma, Primary mediastinal (thymic) large B cell lymphoma

Some of the above Lymphomas here are extremely rare and represent a very small patient population, however, Non-Hodgkin Lymphoma (NHL) has – 81,560 patients/yr in the US………. 743,176 (2018) people in the US living with NHL – 510,000 new cases Globally every year (2018).

https://www.cancer.org/cancer/non-hodgk ... stics.html
https://seer.cancer.gov/statfacts/html/nhl.html
https://pubmed.ncbi.nlm.nih.gov/30895415/

Nishan Sengupta's hiring at Geron while continuing to hold a dual position at JNJ is one of the strongest clues that perhaps JNJ is quietly sitting over on the sidelines? -Kmall

biopearl123
Posts: 1003
Joined: Fri Jul 20, 2018 5:13 pm

Re: Geron continues to build their case

Post by biopearl123 » Tue Sep 27, 2022 4:41 pm

Kmall, when I saw Nishan Sengupta’s name I knew you would find it interesting. Can you share with us how we know he holds a dual position? How do we know he didn’t just leave his J and J position when he was hired by Geron? Thanks, bp

kmall
Posts: 295
Joined: Thu Mar 21, 2019 3:57 pm

Re: Geron continues to build their case

Post by kmall » Tue Sep 27, 2022 5:19 pm

@Bp - Take a look at his resume on LinkedIn.

I highly doubt that an employee of his caliber, being the JNJ - Global/US Access Strategy Lead-IMBRUVICA, B-Cell, Rare Hematology top dog since August 2019, wouldn't take the time to update his resume in reflecting a total departure from that position at JNJ.... ESPECIALLY since he's now on the Geron employee roster. If anyone knew of the JNJ/Geron collaboration/discontinuation it would certainly be Nishan Sengupta.

Even "IF" not updating his resume was the case, which I highly doubt, then there is almost an even stronger argument here for the efficacy, eventual approval and commercialization of Imetelstat.

It certainly appears between the Janssen development team migration to Geron, a satellite office near JNJ Headquarters and now the addition of Nishan Sengupta to the fold, JNJ is behind the scenes working in tandem with Geron management........

Stranger things have happened before, and I've been wrong more times than I can count, so take it for what it is? -Kmall

biopearl123
Posts: 1003
Joined: Fri Jul 20, 2018 5:13 pm

Re: Geron continues to build their case

Post by biopearl123 » Tue Sep 27, 2022 6:05 pm

Thanks Kmall, you have gifted us many dots to connect, sort of like that swarm of dots you see when you activate your new iPhone!

rccola335
Posts: 130
Joined: Sat Sep 28, 2019 10:00 pm

Re: Geron continues to build their case

Post by rccola335 » Wed Sep 28, 2022 12:02 am

I emailed Geron to confirm his employment at JNJ also and got no reply - this was about a month ago

kmall
Posts: 295
Joined: Thu Mar 21, 2019 3:57 pm

Re: Geron continues to build their case

Post by kmall » Wed Sep 28, 2022 12:29 pm

Speaking of building........

Geron continues to build out it's Clinical Operations staff......

Manoj Jivani - Director Clinical Operations, Geron Corporation

Hired - April 2022

4/21/2022 - FOSTER CITY, Calif.-- Geron Corporation (Nasdaq: GERN) reported that it has granted non-statutory stock options to purchase an aggregate of 505,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. Manoj Jivani is one of these newly hired employees.

Maoj's former employers include: Black Diamond Therapeutics, Denovo Biopharma, Tracon Pharmaceuticals

As Geron continues launching new Clinical Trials with additional indications, crucial positions are being filled in order to successfully complete company objectives. The backbone and main driver behind any up and coming Biotech is Clinical Operations. Geron is firing on all cylinders in that department. -Kmall
Last edited by kmall on Wed Sep 28, 2022 1:47 pm, edited 2 times in total.

kmall
Posts: 295
Joined: Thu Mar 21, 2019 3:57 pm

Re: Geron continues to build their case

Post by kmall » Wed Sep 28, 2022 12:40 pm

Known current Geron Employees as of 9/28/2022 and their initial hiring dates –
* Former Janssen employee
+ Part-time or Consultant

Management:
1 - CEO – Dr. John A. Scarlett, MD - 2011
2 - CFO – Olivia K. Bloom - 1994
3 - CAO – Melissa A. Kelly Behrs – 1998
4. – CBO – Edward Koval - 2021
5 - COO – Andrew J. Grethlein - 2012
6 - CCO* – Anil Kapur - 2019
7 - CMO* – Faye Feller, MD - 2019
8 - CLO – Stephen N. Rosenfield - 2011

Clinical – Operations, Science, Development:
Faye Feller*(7), MD – CMO – 2019
9 - Laurie Sherman* – VP Clinical Operations – 2019
10 - Souria Dougherty* - Ex Director Clinical Science - 2019
11 - Tymara Berry – Ex Director Clinical Development - 2020
12 - Sheetal Shah – Sr Director – 2020
13 - Denise Redding – Director - 2021
14 - Jeff Ryel – Director Clinical Operations - 2020
15 - Karie Arnold – Director Clinical Operations –
2021
16 - Brandie Jonas – Sr Director, Clinical Program Management – 2019
17 - F Matthew Bakthasekaran - Sr Manger, Clinical Program Management - 2022
18 - Judy Ho - Sr Manager - 2022
19 - Natasha M - Associate Director, Clinical Research - 2021
20 - Manoj Jivani - Director Clinical Operations - 2022
21 - Kate Turner - Associate Director Clinical Operations - 2022
22 – Carolina Jacobs – Sr Project Manager - 2012
23 - Daria Zielinska – Sr Scientist – 2001
24 - Ron Pruzan – Principal Scientist – 2010
25 – Yelena Polonskaya – Sr Research Associate - 2001
26 - Barbara Mandelkow (Germany) Lab Assistant - 2017
27 - Janet Ahern(+) - Clinical Research Consultant - 2022
28 - Dr. Aleksandra Rizo*(+) - Sr. Medical and Regulatory Advisor - 2019
(currently employed at Vividion and Geron)
29 - Mebratu Gebreyesus(+) - Sr Development Associate - 2010
(currently employed at Bayer, Celltheon and Geron)
30 - Kerry Mundt(+) – CT Assistant – 2010
(currently employed by Pharmacyclics/Abbvie and Geron)

Pharmacovigilance and Drug Safety/Information:
31 - Patti N. – Ex Director Drug Safety – 2020
32 – Annat Ikin - Director Medical Writing – 2021

Business Development:
Melissa A. Kelly Behrs (3) – Chief Alliance Officer – 2014
Edward Koval (4) – CBO - 2021
Anil Kapur* (6) - COO - 2019
33 - Jason Grossman - Ex Director, Commercial Operations - 2022
34 - Nishan Sengupta - VP, Market-Access, Pricing, Evidence Strategy - 2021
35 - Denise Meyer – VP Medical Affairs – 2021
36 - Christopher Cornell - Sr. Field Medical Liaison - 2022
37 - Helen Lee – Sr. Reporting Analyst - 2012
38 - Anthony Kuczynski – Analyst - 2019
39 - Aron Feingold - VP Investor Relations & Corporate Communication - 2022

Finance:
Olivia K. Bloom (2) – CFO – 1994
40 - Karen Boyce – VP -2008
41 - Andrew Good – Ex Director – 2006
42 - Gilian Fong – Director – 2021
43 – Iasko Cable – Sr. Clinical Trial Accountant – 2019
44 – Dave Clark – CPA, Corporate Controller - 2022
45 - Katherine Harmon, CPA, Assistant Controller - 2022

Data Management:
46 - Ben Thorp - Head of Clinical Data Management - 2022
47 - Rana F.* – Director, Statistical Programming - 2020
48 - Sridevi Sridhar, CCDM – Associate Director – 2021

Manufacturing:
49 - Patrick Murphy – VP Manufacturing – 2019
50 - Eric Mueller – Director – 2019
51 - Leslie C. – CMC Director - 2021
52 - Bharat Baral* – CMC Manager – 2021 & 2011
53 - William Garzon-Rodriguez* - Associate Director Drug Product Manufacturing – 2021
54 - Tim Tickner – Director, Supply Chain Management – 2022

Regulatory:
55 - Sharon McBain* - VP Global - 2019
56 - Shirin Mirshamsi* – Director EU – 2019
57 - Ilesh Sanathra* - Director Global – 2020
58 - Nick Lyon – Director – 2020
59 – Ronan Balicanta* Senior Manager, Submissions - 2022
60 - Tarin Araujo - Senior Manager US - 2022

Biostatistics:
61 - Ying Wan* – VP - 2019
62 - Libo Sun* – Director - 2019

Quality Assurance and Quality Control:
63 - Denise Grippo – VP Quality and Compliance – 2019
64 - Samantha Taylor – QA Manager, Document Control – 2007
65 - Joe Denton – Director – 2019
66 - Damanjit Singh – Sr Manager – 2018
67 - Willie Mobley – Materials/Document Specialist - 2007
68 - Leah Wood – Manager – 2021
69 - Murugappa Vedachalam (+) – QA/QC/CMC Consultant - 2019

Legal and Intellectual Property:
Stephen L. Rosenfield (8) – CLO – 2011
70 - Pamela Smith – Associate General Counsel - 1999
71 - Christopher Johnson – Director - 2019
72 - Laura Reederson – Director - 2020
73 - Leslie Mooi – VP IP – 2007
74 - Abby B. – Sr Patent Paralegal - 2014
75 - Cheryl Northern – Sr. Contracts Manager – 2007
76 – Brittney Hernandez – Contracts Manager – 2021

Facilities Operations and Information Technology:
77 - Michael Yamada – VP -2007
78 - Jyoti Shetty – Sr Director IT – 2021
79 - John Albert - Director Information Technology Infrastructure - 2022
80 - Tim W - Associate Director, IT Business Systems - 2022
81 - Miguel Hundelt – Systems Administrator – 2018
82 – Julian Cornejo - Systems Administrator - 2021
83 - Briana Martinez – Ex Assistant - 2006
84 - Julia Mensing – Ex Assistant – 2011
85 - Stacie W. – Ex Assistant - 2020
86 - Mia Pham – Office Manager - 2020

Human Resources:
87 - Shannon Odam – HR Executive -2019
88 - Stephanie Dellari – Director - 2004
89 - Susan Finan – Employee Benefits – 2021
90 - Marisa Cerniglia - Manager, People Operations – 2021
91 – Jennifer Allen - Associate Director, Talent Acquisition – 2022
92 – Fiona McAuliffe – Talent Acquisition Associate - 2022

**This latest "known" Geron employee roster reflects the most recent addition of:

20 - Manoj Jivani - Director Clinical Operations - 2022
Last edited by kmall on Thu Oct 13, 2022 1:27 am, edited 2 times in total.

kmall
Posts: 295
Joined: Thu Mar 21, 2019 3:57 pm

Re: Geron continues to build their case

Post by kmall » Sat Oct 01, 2022 4:32 am

Mystery solved.......

Nishan Sengupta's resume has been officially updated to reflect being solely employed by Geron at this time:

Vice President-Market Access, Pricing, Evidence Strategy
Geron Corporation
Aug 2021 - Present 1 yr 3 mos

Johnson & Johnson
Global/US Access Strategy Lead-IMBRUVICA, B-Cell, Rare Hem
Aug 2015 - Aug 2021 6 yrs 1 mo

Looks like those emails to Aron Feingold helped to clarify this matter. Either way it's a win/win for Geron. Having an employee with over 17yrs of experience in Big Pharma join Geron at this point in his career, especially given his previous employer and title is a tremendous vote of confidence towards the efficacy and eventual approval/commercialization of Imetelstat. -Kmall

Post Reply